KALA BIO, Inc. (KALA) stock
KALANasdaqPharmaceutical PreparationsFiscal year ends December 31
$0.14−0.02 (-13.79%)
Close on Nov 13, 2026Market cap $2.68MP/E –Yield –
Kala Bio operating margin
Operating margin is operating income as a percentage of revenue.
Kala Bio's operating margin for the twelve months ending Dec 31, 2022 was -2099.3%. For fiscal 2022 it was -2099.3%, against -1158.8% the year before. The highest annual figure on record is -1158.8% in fiscal 2021.
Annual operating margin
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| FY2022 | Dec 31, 2022 | -2099.3% | −940.6 |
| FY2021 | Dec 31, 2021 | -1158.8% | +353.8 |
| FY2020 | Dec 31, 2020 | -1512.6% | −60.1 |
| FY2019 | Dec 31, 2019 | -1452.5% | +33983.1 |
| FY2015 | Dec 31, 2015 | -35435.6% | – |
Quarterly operating margin
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| Q3 FY2022 | Sep 30, 2022 | -3468.8% | −2618.8 |
| Q2 FY2022 | Jun 30, 2022 | -1236.8% | −284.8 |
| Q1 FY2022 | Mar 31, 2022 | -2253.2% | −1386.3 |
| Q4 FY2021 | Dec 31, 2021 | -2522.4% | −1227.3 |
| Q3 FY2021 | Sep 30, 2021 | -850.0% | +314.0 |
| Q2 FY2021 | Jun 30, 2021 | -952.0% | +1602.6 |
| Q1 FY2021 | Mar 31, 2021 | -866.9% | +1012.2 |
| Q4 FY2020 | Dec 31, 2020 | -1295.1% | +416.5 |
| Q3 FY2020 | Sep 30, 2020 | -1164.1% | +322.3 |
| Q2 FY2020 | Jun 30, 2020 | -2554.6% | −1465.2 |
| Q1 FY2020 | Mar 31, 2020 | -1879.1% | −143.9 |
| Q4 FY2019 | Dec 31, 2019 | -1711.6% | – |
| Q3 FY2019 | Sep 30, 2019 | -1486.4% | – |
| Q2 FY2019 | Jun 30, 2019 | -1089.5% | – |
| Q1 FY2019 | Mar 31, 2019 | -1735.2% | – |
See a number that looks wrong?